Two year randomized controlled trial of etidronate in rheumatoid arthritis: Changes in serum aminoterminal telopeptides correlate with radiographic progression of disease

Journal of Rheumatology

Volumn 30, Issue 3, 2003, Pages 468-473

  Valleala, Heikki ^a   Laasonen, Leena ^a   Koivula, Marja Kaisa ^c   Mandelin, Jami ^b   Friman, Claes ^d   Risteli, Juha ^c   Konttinen, Yrjö T ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF OULU   (Finland)

^d NONE

Author keywords

Collagen markers; Etidronate bone; Rheumatoid arthritis

Indexed keywords

AMINOTERMINAL TELOPEPTIDE; ANTIRHEUMATIC AGENT; CALCIUM CARBONATE; COLLAGEN TYPE 1; CROSSLINKED C TELOPEPTIDE; ETIDRONIC ACID; PEPTIDE FRAGMENT; STEROID; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE EROSION; BONE METABOLISM; CELL TYPE; CLINICAL ARTICLE; CLINICAL TRIAL; COLLAGEN DEGRADATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS LINKING; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DRUG EFFECT; FEMALE; FOOT RADIOGRAPHY; HAND RADIOGRAPHY; HUMAN; JOINT RADIOGRAPHY; MALE; OPEN STUDY; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SINGLE BLIND PROCEDURE;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; COLLAGEN; COLLAGEN TYPE I; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; ETIDRONIC ACID; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN;

EID: 0347721769     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Bromley M, Woolley DE. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum 1984;27:968-75.
2. Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998;152:943-51.
3. Gravallese EM, Goldring SR. Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis. Arthritis Rheum 2000;43:2143-51.
4. Eggelmeijer F, Papapoulos SE, Westedt ML, Van Paassen HC, Dijkmans BA, Breedveld FC. Bone metabolism in rheumatoid arthritis; relation to disease activity. Br J Rheumatol 1993;32:387-91.
5. Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK. Reduced bone mineral density in male rheumatoid arthritis patients: frequencies and associations with demographic and disease variables in ninety-four patients in the Oslo County Rheumatoid Arthritis Register. Arthritis Rheum 2000;43:2776-84.
6. Woo T, Adachi JD. Role of bisphosphonates and calcitonin in the prevention and treatment of osteoporosis. Best Pract Res Clin Rheumatol 2001;15:469-81.
7. Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999;25:97-106.
8. Ralston SH, Hacking L, Willocks L, Bruce F, Pitkeathly DA. Clinical, biochemical, and radiographic effects of aminohydroxypropylidene bisphosphonate treatment in rheumatoid arthritis. Ann Rheum Dis 1989;48:396-9.
9. Eggelmeijer F, Papapoulos SE, van Paassen HC, et al. Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. Arthritis Rheum 1996;39:396-402.
10. Osterman T, Kippo K, Lauren L, Hannuniemi R, Sellman R. Effect of clodronate on established collagen-induced arthritis in rats. Inflamm Res 1995;44:258-63.
11. Nakamura M, Ando T, Abe M, Kumagai K, Endo Y. Contrast between effects of aminobisphosphonates and non-aminobisphosphonates on collagen-induced arthritis in mice. Br J Pharmacol 1996;119:205-12.
12. Melkko J, Kauppila S, Niemi S, et al. Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem 1996;42:947-54.
13. Hakala M, Aman S, Luukkainen R, et al. Application of markers of collagen metabolism in serum and synovial fluid for assessment of disease process in patients with rheumatoid arthritis. Ann Rheum Dis 1995;54:886-90.
14. Cortet B, Flipo RM, Pigny P, et al. Is bone turnover a determinant of bone mass in rheumatoid arthritis? J Rheumatol 1998;25:2339-44.
15. Paimela L, Leirisalo-Repo M, Risteli L, Hakala M, Helve T, Risteli J. Type I collagen degradation product in serum of patients with early rheumatoid arthritis: relationship to disease activity and radiological progression in a 3-year follow-up. Br J Rheumatol 1994;33:1012-6.
16. Kotaniemi A, Isomaki H, Hakala M, Risteli L, Risteli J. Increased type I collagen degradation in early rheumatoid arthritis. J Rheumatol 1994;21:1593-6.
17. Hakala M, Risteli L, Manelius J, Nieminen P, Risteli J. Increased type I collagen degradation correlates with disease severity in rheumatoid arthritis. Ann Rheum Dis 1993;52:866-9.
18. Al-Awadhi A, Olusi S, Al-Zaid N, Prabha K. Serum concentrations of interleukin 6, osteocalcin, intact parathyroid hormone, and markers of bone resorption in patients with rheumatoid arthritis. J Rheumatol 1999;26:1250-6.
19. Clemens JD, Herrick MV, Singer FR, Eyre DR. Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption. Clin Chem 1997;43:2058-63.
20. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
21. Steinbrocker O, Traeger CH, Batterman EC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949;140:659-62.
22. Van Gestel AM, Haagsma CJ, van Riel PLCM. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998;41:1845-50.
23. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 1993;39:635-40.
24. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 1999;26:743-5.
25. Garnero P, Borel O, Byrjalsen I, et al. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem 1998;273:32347-52.
26. Inui T, Ishibashi O, Origane Y, Fujimori K, Kokubo T, Nakajima M. Matrix metalloproteinases and lysosomal cysteine proteases in osteoclasts contribute to bone resorption through distinct modes of action. Biochem Biophys Res Commun 1999;258:173-8.
27. Sassi ML, Eriksen H, Risteli L, et al. Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K. Bone 2000;26:367-73.
28. Atley LM, Mort JS, Lalumiere M, Eyre DR. Proteolysis of human bone collagen by cathepsin K: characterization of the cleavage sites generating by cross-linked N-telopeptide neoepitope. Bone 2000;26:241-7.
29. Konttinen YT, Ainola M, Valleala H, et al. Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis 1999;58:691-7.
30. Close DR. Matrix metalloproteinase inhibitors in rheumatic diseases. Ann Rheum Dis 2001;60 Suppl 3:iii62-7.
31. Saarto T, Blomqvist C, Risteli J, Risteli L, Sarna S, Elomaa I. Aminoterminal propeptide of type I procollagen (PINP) correlates to bone loss and predicts the efficacy of antiresorptive therapy in pre- and post-menopausal non-metastatic breast cancer patients. Br J Cancer 1998;78:240-5.
32. Scariano JK, Glew RH, Bou-Serhal CE, Clemens JD, Garry PJ, Baumgartner RN. Serum levels of cross-linked N-telopeptides and aminoterminal propeptides of type I collagen indicate low bone mineral density in elderly women. Bone 1998;23:471-7.
33. Chandani AK, Scariano JK, Glew RH, Clemens JD, Garry PJ, Baumgartner RN. Bone mineral density and serum levels of aminoterminal propeptides and cross-linked N-telopeptides of type I collagen in elderly men. Bone 2000;26:513-8.
34. Greenspan SL, Rosen HN, Parker RA. Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type I predict long-term response to alendronate therapy in elderly women. J Clin Endocrinol Metab 2000;85:3537-40.
35. MacDonald BR, Gowen M. Emerging therapies in osteoporosis. Best Pract Res Clin Rheumatol 2001;15:483-96.
36. Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304-9.